Gain Therapeutics (NASDAQ:GANX) Stock Rating Upgraded by Roth Capital

Roth Capital upgraded shares of Gain Therapeutics (NASDAQ:GANX) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

GANX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, November 25th. Roth Mkm began coverage on Gain Therapeutics in a report on Friday. They issued a “buy” rating and a $7.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Wednesday, August 14th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a report on Friday, August 9th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $7.25.

Gain Therapeutics Stock Performance

Shares of GANX opened at $1.79 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The stock has a 50 day moving average price of $2.09 and a two-hundred day moving average price of $1.68. The firm has a market capitalization of $47.47 million, a P/E ratio of -1.63 and a beta of 0.21. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $5.33.

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors have recently bought and sold shares of the company. Warberg Asset Management LLC purchased a new position in Gain Therapeutics in the second quarter valued at approximately $66,000. Renaissance Technologies LLC lifted its stake in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after purchasing an additional 72,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the last quarter. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics in the second quarter valued at approximately $422,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.